Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
Amuvatinib
CHF 0.00
In stock
SYN-1056-M0011 mgCHF 142.00
SYN-1056-M0055 mgCHF 270.00
SYN-1056-M01010 mgCHF 447.00
SYN-1056-M05050 mgCHF 1'206.00
SYN-1056-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | MP-470 |
| Product Type | Chemical |
| Properties | |
| Formula | C23H21N5O3S |
| MW | 447.5 |
| CAS | 850879-09-3 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO or ethanol. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: PDGFR | Kinase Group: RTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | FOFDIMHVKGYHRU-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Amuvatinib is a potent, novel and orally active multi-targeted tyrosine kinase inhibitor, which inhibits a number of validated tumor targets including c-kit, PDGFRα and flt3, with IC(50) values of 10nM, 40nM and 81nM respectively.
Product References
- MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer: W. Qi, et al.; BMC Cancer 9, 142 (2009)
Related Products
